TY  - JOUR
AU  - Harrer, E.
AU  - Bäuerle, M.
AU  - Ferstl, B.
AU  - Chaplin, I. T.
AU  - Petzold, B.
AU  - Mateo, L.
AU  - Handley, A.
AU  - Tzatzaris, M.
AU  - Vollmar, J.
AU  - Bermann, S.
AU  - Rittmaier, M.
AU  - Eismann, K.
AU  - Miller, S.
AU  - Kalden, J. R.
AU  - Spriewald, B.
AU  - Willbold, D.
AU  - Harrer, T.
TI  - Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption
JO  - Antiviral therapy
VL  - 10
SN  - 1359-6535
CY  - London
PB  - International Medical Press
M1  - PreJuSER-45558
SP  - 285 - 300
PY  - 2005
N1  - Record converted from VDB: 12.11.2012
AB  - The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 > 400/mu l) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA-nef was well tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA-nef was associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4-76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57-76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4-38) weeks. This study has demonstrated that MVA-nef is safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations.
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000231962300011
UR  - https://juser.fz-juelich.de/record/45558
ER  -